Johanna E E Pouw
Overview
Explore the profile of Johanna E E Pouw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wijngaarden J, Slebe M, Pouw J, Oprea-Lager D, Schuit R, Dickhoff C, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(2):719-729.
PMID: 39377810
Introduction: The novel positron emission tomography (PET) imaging tracer, [F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was...
2.
Miedema I, Pouw J, Kwakman A, Zwezerijnen G, Huisman M, Timmer F, et al.
J Immunother Cancer
. 2024 Jun;
12(6).
PMID: 38886117
Introduction: Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using F-BMS-986192...
3.
Wijngaarden J, Ahbari A, Pouw J, Greuter H, Bahce I, Zwezerijnen G, et al.
EJNMMI Phys
. 2024 Feb;
11(1):16.
PMID: 38321232
Background: PET scans using zirconium-89 labelled monoclonal antibodies (Zr-mAbs), known as Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of Zr-mAbs...
4.
Pouw J, Hashemi S, Huisman M, Wijngaarden J, Slebe M, Oprea-Lager D, et al.
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38302416
Background: In patients with locally advanced unresectable non-small cell lung cancer (NSCLC), durvalumab, an anti-programmed cell death ligand-1 (PD-L1) antibody, has shown improved overall survival when used as consolidation therapy...
5.
Miedema I, Wijngaarden J, Pouw J, Zwezerijnen G, Sebus H, Smit E, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067257
Introduction: Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific and...
6.
Wijngaarden J, Huisman M, Pouw J, Menke-van der Houven van Oordt C, Jauw Y, Boellaard R
EJNMMI Res
. 2022 Sep;
12(1):54.
PMID: 36065038
Purpose: Zirconium-89-immuno-positron emission tomography (Zr-immuno-PET) has enabled visualization of zirconium-89 labelled monoclonal antibody (Zr-mAb) uptake in organs and tumors in vivo. Patlak linearization of Zr-immuno-PET quantification data allows for separation...
7.
Slebe M, Pouw J, Hashemi S, Menke-van der Houven van Oordt C, Yaqub M, Bahce I
Lung Cancer
. 2022 Jun;
169:84-93.
PMID: 35679715
Immune oncology therapy (IO) has now become an important treatment option for patients with a non-small cell lung cancer (NSCLC). However, a substantial proportion of patients still fails to benefit...
8.
Geboers B, Timmer F, Ruarus A, Pouw J, Schouten E, Bakker J, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359801
Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor's immunosuppressive...